Full Press Release Details
Poland and U.K. Regulatory Authorities - URPL and MHRA -
Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
NEW YORK and LONDON, March 29,
2023 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies
for autoimmune and inflammatory diseases, today announced regulatory authorities in Poland (Office for Registration of Medicinal Products,
Medical Devices and Biocidal Products/URPL) and the U.K. (Medicines & Healthcare products Regulatory Agency/MHRA) have approved
amendments to the company's Investigational Medicinal Product Dossier (IMPD) and Clinical Trial Authorisation (CTA), respectively,
for clinical use of the third-generation drug substance manufacturing process that increases the final yield of nomacopan by at least
5-fold. Nomacopan is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical
trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
"The clearance by regulators in the U.K. and Poland of Akari's
newer, enhanced manufacturing process for nomacopan is another important step forward in our progress toward the pivotal Part B in
our clinical trials in pediatric HSCT-TMA," said Rachelle Jacques, President and Chief Executive Officer of Akari Therapeutics.
The Phase 3 study of nomacopan in pediatric HSCT-TMA includes clinical
trial sites in Poland, the U.K. and U.S.
About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing
advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant
inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari's pipeline includes a Phase 3 clinical trial program
investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has
been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric
HSCT-TMA. Akari's pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of
long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect
our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available
to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected
in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations,
or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking
statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company
include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties
of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan
and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional
indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any
other product candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to
realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties
involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product
candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products
brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected risks
associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property
rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing
arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases
and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission,
including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the
forward-looking statements contained in this press release.
For more information